October 22, 2024
1 min watch
Save
VIDEO: In phase 2 trial, ANX007 shows protection from vision loss in patients with GA
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Barbara Blodi, MD, discusses results from the ARCHER trial presented at the American Society of Retina Specialists annual meeting.
The data from the phase 2 clinical trial indicate that ANX007 (Annexon Biosciences), a selective inhibitor of C1q, may show a protection from vision loss in patients with geographic atrophy, according to Blodi, professor in the department of ophthalmology and visual sciences at the University of Wisconsin School of Medicine and Public Health.
“They’re really looking at that as an important functional outcome rather than solely the growth of GA,” she said.
Reference:
- Pearlman J, et al. Preservation of vision by ANX007: Clinical results and anatomic changes from the phase 2 ARCHER trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Blodi reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.